dr. reddys laboratories ltd - RDY

RDY

Close Chg Chg %
13.97 0.24 1.68%

Closed Market

14.21

+0.24 (1.68%)

Volume: 1.34M

Last Updated:

Nov 22, 2024, 3:59 PM EDT

Company Overview: dr. reddys laboratories ltd - RDY

RDY Key Data

Open

$14.20

Day Range

14.12 - 14.30

52 Week Range

12.90 - 16.89

Market Cap

$11.67B

Shares Outstanding

834.08M

Public Float

834.06M

Beta

0.56

Rev. Per Employee

N/A

P/E Ratio

18.22

EPS

$0.77

Yield

57.78%

Dividend

$0.40

EX-DIVIDEND DATE

Jul 30, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

852.68K

 

RDY Performance

1 Week
 
0.21%
 
1 Month
 
-7.04%
 
3 Months
 
-13.58%
 
1 Year
 
4.06%
 
5 Years
 
78.84%
 

RDY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 36
Full Ratings ➔

About dr. reddys laboratories ltd - RDY

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

RDY At a Glance

Dr. Reddy's Laboratories Ltd.
Door No. 8-2-337
Hyderabad, Telangana 500034
Phone 91-40-49002900 Revenue 3.37B
Industry Pharmaceuticals: Major Net Income 672.58M
Sector Health Technology 2024 Sales Growth 10.211%
Fiscal Year-end 03 / 2025 Employees 27,048
View SEC Filings

RDY Valuation

P/E Current 18.219
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.147
Price to Sales Ratio 3.626
Price to Book Ratio 3.638
Price to Cash Flow Ratio 22.522
Enterprise Value to EBITDA 12.087
Enterprise Value to Sales 3.408
Total Debt to Enterprise Value 0.021

RDY Efficiency

Revenue/Employee 124,662.89
Income Per Employee 24,866.13
Receivables Turnover 3.27
Total Asset Turnover 0.788

RDY Liquidity

Current Ratio 2.583
Quick Ratio 1.921
Cash Ratio 0.848

RDY Profitability

Gross Margin 55.705
Operating Margin 22.879
Pretax Margin 25.692
Net Margin 19.947
Return on Assets 15.71
Return on Equity 21.786
Return on Total Capital 18.663
Return on Invested Capital 21.482

RDY Capital Structure

Total Debt to Total Equity 7.136
Total Debt to Total Capital 6.661
Total Debt to Total Assets 5.166
Long-Term Debt to Equity 2.135
Long-Term Debt to Total Capital 1.993
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Dr. Reddys Laboratories Ltd - RDY

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
2.56B 2.88B 3.06B 3.37B
Sales Growth
+3.79% +12.59% +6.33% +10.21%
Cost of Goods Sold (COGS) incl D&A
1.26B 1.43B 1.41B 1.49B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
172.37M 158.69M 157.23M 179.26M
Depreciation
114.86M 109.41M 107.20M 115.66M
Amortization of Intangibles
57.51M 49.28M 50.03M 63.59M
COGS Growth
+3.09% +13.89% -1.80% +6.17%
Gross Income
1.30B 1.44B 1.65B 1.88B
Gross Income Growth
+4.48% +11.32% +14.40% +13.65%
Gross Profit Margin
+50.78% +50.21% +54.02% +55.70%
2021 2022 2023 2024 5-year trend
SG&A Expense
868.27M 984.65M 1.01B 1.11B
Research & Development
208.37M 220.27M 228.50M 262.12M
Other SG&A
659.90M 764.38M 777.92M 848.80M
SGA Growth
+3.28% +13.40% +2.21% +10.38%
Other Operating Expense
(1.91M) (2.76M) (3.48M) (4.08M)
Unusual Expense
115.69M 101.49M 8.70M 36.24K
EBIT after Unusual Expense
315.75M 361.31M 641.03M 771.43M
Non Operating Income/Expense
46.65M 75.59M 123.29M 115.54M
Non-Operating Interest Income
11.13M 12.95M 14.68M 27.51M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
13.07M 12.86M 17.77M 20.67M
Interest Expense Growth
-5.75% -1.60% +38.20% +16.31%
Gross Interest Expense
18.66M 18.51M 24.97M 31.71M
Interest Capitalized
5.59M 5.65M 7.20M 11.04M
Pretax Income
349.34M 424.04M 746.55M 866.31M
Pretax Income Growth
+41.78% +21.38% +76.06% +16.04%
Pretax Margin
+13.67% +14.74% +24.40% +25.69%
Income Tax
123.59M 117.17M 190.38M 195.50M
Income Tax - Current - Domestic
78.79M 56.10M 109.10M 167.58M
Income Tax - Current - Foreign
31.29M 29.94M 50.89M 67.45M
Income Tax - Deferred - Domestic
36.86M 29.06M 48.42M 11.69M
Income Tax - Deferred - Foreign
(23.34M) 2.07M (18.03M) (51.21M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
232.21M 316.31M 560.77M 672.58M
Minority Interest Expense
- - - -
-
Net Income
232.21M 316.31M 560.77M 672.58M
Net Income Growth
-15.56% +36.22% +77.29% +19.94%
Net Margin Growth
+9.09% +10.99% +18.33% +19.95%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
232.21M 316.31M 560.77M 672.58M
Preferred Dividends
- - - -
-
Net Income Available to Common
232.21M 316.31M 560.77M 672.58M
EPS (Basic)
0.28 0.3814 0.6755 0.8084
EPS (Basic) Growth
-15.61% +36.21% +77.11% +19.67%
Basic Shares Outstanding
829.22M 829.41M 830.17M 831.97M
EPS (Diluted)
0.2792 0.3803 0.6741 0.8069
EPS (Diluted) Growth
-15.68% +36.21% +77.25% +19.70%
Diluted Shares Outstanding
831.58M 831.69M 831.94M 833.54M
EBITDA
603.81M 621.49M 806.96M 950.72M
EBITDA Growth
+4.15% +2.93% +29.84% +17.82%
EBITDA Margin
+23.63% +21.60% +26.38% +28.20%

Snapshot

Average Recommendation HOLD Average Target Price 16.173
Number of Ratings 36 Current Quarters Estimate 0.215
FY Report Date 12 / 2024 Current Year's Estimate 0.817
Last Quarter’s Earnings 0.178 Median PE on CY Estimate N/A
Year Ago Earnings 0.80 Next Fiscal Year Estimate 0.815
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 4 33 29
Mean Estimate 0.21 0.22 0.82 0.82
High Estimates 0.26 0.25 0.96 0.96
Low Estimate 0.19 0.19 0.46 0.59
Coefficient of Variance 15.47 12.21 11.24 10.69

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9 9
OVERWEIGHT 4 2 2
HOLD 12 10 10
UNDERWEIGHT 4 7 8
SELL 7 9 7
MEAN Hold Hold Hold

Dr. Reddys Laboratories Ltd in the News